Salarius Pharmaceuticals Inc (SLRX NASDAQ) stock market data APIs
$0.8217
0.09(11%)
as of December 5, 2025
Try our APIs with
free plan!
Salarius Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Prev. Close
0.8217
Open
0.9085
High
0.9153
Low
0.8153
52 wk Range
0.7106-55.05
Market Cap
4 836 K
Shares Outstanding
5 862 K
EPS
-1.8137
Beta
0.396
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Salarius Pharmaceuticals Inc data using free add-ons & libraries
Get Salarius Pharmaceuticals Inc Fundamental Data
Salarius Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -5 563 679
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Salarius Pharmaceuticals Inc News
New
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that i...
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies
Company Logo Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft ti...
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company ...
Strong Earnings and Biotech Resilience Define the Midweek Momentum
DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giant...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
